**Curriculum Vitae**

Name: Joo-Yong Hahn, MD, PhD

Address: Division of Cardiology, Department of Medicine,

Samsung Medical Center, Sungkyunkwan University School of Medicine,

81 Irwon-ro, Gangnam-gu, Seoul, 06275, Republic of Korea

Tel: 82-2-3410-6653

Fax: 82-2-3410-3849

E-mail: [jyhahn@skku.edu](mailto:jyhahn@skku.edu)

PROFESSIONAL LICENSURE: Medical Doctor (No. 59932)

1. Current position:

Professor

Department of Internal Medicine

Heart Vascular Stroke Institue, Samsung Medical Center,

Sungkyunkwan University School of Medicine, Seoul, Korea

2. Educational background

1990 - 1996 Master, College of Medicine, Seoul National University

1999 - 2001 Bachelor, College of Medicine, Seoul National University

2004 - 2006 Ph. Doctor, College of Medicine, Seoul National University

3. Career

1996 - 1997 Internship, Seoul National University Hospital

1997 - 2001 Residency, Internal Medicine, Seoul National University Hospital

2001 - 2004 Military doctor for a military service

2004 - 2006 Fellowship, Department of Cardiology, Seoul National University Hospital

2006.3 - 2008.2 Clinical assistant professor, Department of Cardiology, Samsung Medical Center

2008.3 – 2012.3 Assistant professor of Internal Medicine, Department of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine

2010.8 -2012.1 Postdoctoral fellow, Division of Cardiovascular Medicine, Stanford University School of Medicine

2012.4 –2018.3 Associate professor of Internal Medicine, Department of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine

2018.4 - Professor of Internal Medicine, Department of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine

4. Research interest

1) Coronary artery disease

2) Percutaneous coronary intervention

3) Antiplatelet therapy

4) Myocardial infarction

<**Major publication list>**

Kim J,Kang D, Park H, Kang M, Park TK, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Guallar E, Cho J, **Hahn JY**. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020 Jun 15:ehaa376. doi: 10.1093/eurheartj/ehaa376. Online ahead of print. (Corresponding author) (IF 22.673)

**Hahn JY**, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC; SMART-CHOICE Investigators. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019 Jun 25;321(24):2428-2437. doi: 10.1001/jama.2019.8146. (Corresponding author) (IF 51.3)

**Hahn JY**, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH, Kim BO, Cho JH, Suh IW, Kim DI, Park HK, Park JS, Choi WG, Lee WS, Kim J, Choi KH, Park TK, Lee JM, Yang JH, Choi JH, Choi SH, Gwon HC; SMART-DATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018 Mar 31;391(10127):1274-1284 (IF 53.254)

Lee JM, Rhee TM, **Hahn JY**, Kim HK, Park J, Hwang DY, Choi KH, Kim JH, Park TK, Yang JH, Song YB, Choi JH, Choi SH, Koo BK, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon HC, Kim JH, Kim HS, Jeong MH. Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction With Cardiogenic Shock. J Am Coll Cardiol. 2018 Feb 27;71(8):844-856. (Corresponding author) (IF 19.896).

Yang JH, **Hahn JY**, Song YB, Choi SH, Choi JH, Lee SH, Jeong MH, Choi DJ, Park JS, Park HS, Gwon HC Angiotensin receptor blocker therapy in patients with ST-segment elevation myocardial infarction with preserved left ventricular systolic function: a prospective cohort study. BMJ 2014 Nov 14;349:g6650. (Corresponding author) (IF 17.4).

**Hahn JY**, Song YB, Kim EK, Yu CW, Bae JW, Chung WY, Choi SH, Choi JH, Bae JH, An KJ, Park JS, Oh JH, Kim SW, Hwang JY, Ryu JK, Park HS, Lim DS, Gwon HC. [Ischemic Postconditioning during Primary Percutaneous Coronary Intervention: The POST Randomized Trial.](http://www.ncbi.nlm.nih.gov/pubmed/24068776) Circulation. 2013 Oct 22;128(17):1889-96. (IF 15.202).

**Hahn JY**, Chun WJ, Kim JH, Song YB, Oh JH, Koo BK, Rha SW, Yu CW, Park JS, Jeong JO, Choi SH, Choi JH, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Kim HS, Gwon HC. [Predictors and Outcomes of Side Branch Occlusion after Main Vessel Stenting in Coronary Bifurcation Lesions: Results from the COBIS (COronary BIfurcation Stenting) II Registry.](http://www.ncbi.nlm.nih.gov/pubmed/23954335) J Am Coll Cardiol. 2013 Oct 29;62(18);62:1654-9 (IF 15.343).

Gwon HC, **Hahn JY**, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. [Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.](http://www.ncbi.nlm.nih.gov/pubmed/22179532) Circulation. 2012 Jan 24;125(3):505-13 (IF 15.202) (Co-first author).

Song YB, **Hahn JY**, Choi SH, Choi JH, Lee SH, Jeong MH, Kim HS, Seong IW, Yang JY, Rha SW, Jang Y, Yoong JH, Tahk SJ, Seung KB, Park SJ, Gwon HC. Sirolimus-Eluting versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations: Results from the COBIS (COronary BIfurcation Stenting) Registry. J Am Coll Cardiol. 2010 Apr 20;55(16):1743-50 (IF 12.640) (Co-first author).

**Hahn JY**, Song YB, Lee SY, Choi JH, Choi SH, Kim DK, Lee SH Gwon HC. Serial Intravascular Ultrasound Analysis of the Main and Side Branches in Bifurcation Lesions Treated with the T-Stenting Technique. J Am Coll Cardiol. 2009 Jul 7;54(2):110-117 (IF 11.438).

**Hahn JY**, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, Bae JW, Oh BH, Park YB, Kim HS. Pretreatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction.J Am Coll Cardiol. 2008;51:933-43 (IF 11.054).